Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests - Summary Of Non-controlling Interests in Consolidated Entities (Detail)

v3.10.0.1
Non-Controlling Interests - Summary Of Non-controlling Interests in Consolidated Entities (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Noncontrolling Interest [Line Items]          
NCI equity share     $ 83,637   $ 100,889
Net gain/(loss) attributable to non-controlling interests $ (14,105) $ (5,584) (31,305) $ (8,164) (32,960)
Non-controlling interests in consolidated entities 52,332   52,332   67,929
Avenue [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share [1]     12,865   17,454
Net gain/(loss) attributable to non-controlling interests [1]     (9,631)   (4,646)
Non-controlling interests in consolidated entities [1] $ 3,234   $ 3,234   $ 12,808
Non-controlling ownership [1] 64.50%   64.50%   66.10%
Coronado SO [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (290)   $ (236)
Net gain/(loss) attributable to non-controlling interests     0   (54)
Non-controlling interests in consolidated entities $ (290)   $ (290)   $ (290)
Non-controlling ownership 13.00%   13.00%   13.00%
Mustang Therapeutics, Inc [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share [1]     $ 37,669   $ 48,740
Net gain/(loss) attributable to non-controlling interests [1]     (6,729)   (11,911)
Non-controlling interests in consolidated entities [1] $ 30,940   $ 30,940   $ 36,829
Non-controlling ownership [1] 60.00%   60.00%   61.60%
Checkpoint Therapeutics, Inc [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share [2]     $ 24,543   $ 21,635
Net gain/(loss) attributable to non-controlling interests [2]     (9,482)   (12,314)
Non-controlling interests in consolidated entities [2] $ 15,061   $ 15,061   $ 9,321
Non-controlling ownership [2] 67.50%   67.50%   62.00%
JMC [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (459)   $ (469)
Net gain/(loss) attributable to non-controlling interests     165   7
Non-controlling interests in consolidated entities $ (294)   $ (294)   $ (462)
Non-controlling ownership 6.30%   6.30%   6.30%
Helocyte [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (3,203)   $ (1,907)
Net gain/(loss) attributable to non-controlling interests     (91)   (1,193)
Non-controlling interests in consolidated entities $ (3,294)   $ (3,294)   $ (3,100)
Non-controlling ownership 19.80%   19.80%   20.00%
Cellvation [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (418)   $ (259)
Net gain/(loss) attributable to non-controlling interests     (91)   (96)
Non-controlling interests in consolidated entities $ (509)   $ (509)   $ (355)
Non-controlling ownership 21.60%   21.60%   21.50%
Caelum [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (2,121)   $ (815)
Net gain/(loss) attributable to non-controlling interests     (1,474)   (1,262)
Non-controlling interests in consolidated entities $ (3,595)   $ (3,595)   $ (2,077)
Non-controlling ownership 33.90%   33.90%   34.70%
National Holdings [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ 15,805   $ 17,021
Net gain/(loss) attributable to non-controlling interests     (3,628)   (1,216)
Non-controlling interests in consolidated entities $ 12,177   $ 12,177   $ 15,805
Non-controlling ownership 43.40%   43.40%   43.40%
Aevitas [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (407)   $ (126)
Net gain/(loss) attributable to non-controlling interests     (184)   (168)
Non-controlling interests in consolidated entities $ (591)   $ (591)   $ (294)
Non-controlling ownership 37.00%   37.00%   35.40%
Cyprium [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (183)   $ (143)
Net gain/(loss) attributable to non-controlling interests     (50)   (15)
Non-controlling interests in consolidated entities $ (233)   $ (233)   $ (158)
Non-controlling ownership 10.80%   10.80%   11.10%
Tamid [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share     $ (164)   $ (6)
Net gain/(loss) attributable to non-controlling interests     (110)   (92)
Non-controlling interests in consolidated entities $ (274)   $ (274)   $ (98)
Non-controlling ownership 24.00%   24.00%   24.00%
[1] Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.
[2] Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.